Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2009

Open Access 01-06-2009 | Research article

Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA)

Authors: Jane T Osterhaus, Oana Purcaru, Lance Richard

Published in: Arthritis Research & Therapy | Issue 3/2009

Login to get access

Abstract

Introduction

The rheumatoid arthritis-specific Work Productivity Survey (WPS-RA) measures the impact of rheumatoid arthritis (RA) and treatment on patient productivity within and outside the home. It contains nine questions addressing employment status, productivity within and outside the home, and daily activities. The objective of this paper was to evaluate the discriminant validity, responsiveness, and reliability of the WPS-RA in patients with active RA.

Methods

Two hundred twenty subjects (mean age was 53.8 years, 83.6% were female, mean disease duration was 9.54 years, mean number of disease-modifying anti-rheumatic drugs failed was 2, and 38.6% were employed outside the home) in a phase III, 24-week, double-blind, placebo-controlled trial completed the WPS-RA at baseline and every 4 weeks until withdrawal/study completion. Validity was evaluated via known groups using baseline data (first and third quartiles of subjects' Health Assessment Questionnaire – Disability Index [HAQ-DI] scores and Short Form-36 health survey [SF-36] scores). To evaluate responsiveness, mean changes in WPS-RA at week 24 were compared between American College of Rheumatology 20% improvement criteria (ACR20) (or HAQ-DI) responders and non-responders. Standardized response mean (SRM) was also used to quantify responsiveness. All group comparisons were conducted using a non-parametric bootstrap-t method.

Results

Subjects with lower HAQ-DI or SF-36 scores generally had statistically greater RA-associated losses in productivity within and outside the home compared with subjects with higher scores (25 of 32 evaluations were statistically significant). Smallest differences between groupswere seen in work absenteeism and days with outside help. At week 24, ACR20 and HAQ-DI responders reported large improvements in productivity within and outside the home; non-responders reported mainly a worsening in productivity (P ≤ 0.05). Effect size for productivity changes in ACR20 or HAQ-DI responders was moderate to large for six out of eight items (SRM = 0.48 to 1.12). The effect size was small for work absenteeism and days with outside help. (SRM = 0.4 and 0.24, respectively). In non-responders, the magnitude of change was negligible (SRM < 0.1) or small (SRM < 0.3).

Conclusions

The WPS-RA has demonstrated properties of discriminative validity, reliability, and responsiveness for the measurement of productivity within and outside the home in subjects with active RA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW: The costs of arthritis. Arthritis Rheum. 2003, 49: 101-113. 10.1002/art.10913.CrossRefPubMed Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW: The costs of arthritis. Arthritis Rheum. 2003, 49: 101-113. 10.1002/art.10913.CrossRefPubMed
2.
go back to reference Burton W, Morrison A, Maclean R, Ruderman E: Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006, 56: 18-27. 10.1093/occmed/kqi171.CrossRef Burton W, Morrison A, Maclean R, Ruderman E: Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006, 56: 18-27. 10.1093/occmed/kqi171.CrossRef
3.
go back to reference Wolfe F, Hawley DJ: The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998, 25: 2108-2117.PubMed Wolfe F, Hawley DJ: The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998, 25: 2108-2117.PubMed
4.
go back to reference Verstappen SM, Boonen A, Verkleij H, Bijlsma JWJ, Buskens E, Jacobs JWG, on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group: Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis. 2005, 64: 1754-1760. 10.1136/ard.2004.033977.PubMedCentralCrossRefPubMed Verstappen SM, Boonen A, Verkleij H, Bijlsma JWJ, Buskens E, Jacobs JWG, on behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group: Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis. 2005, 64: 1754-1760. 10.1136/ard.2004.033977.PubMedCentralCrossRefPubMed
5.
go back to reference Yelin E: Work disability in rheumatic diseases. Curr Opin Rheumatol. 2007, 19: 91-96. 10.1097/BOR.0b013e3280126b66.CrossRefPubMed Yelin E: Work disability in rheumatic diseases. Curr Opin Rheumatol. 2007, 19: 91-96. 10.1097/BOR.0b013e3280126b66.CrossRefPubMed
6.
go back to reference Jantti J, Aho K, Kaarela K, Kautiainen H: Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20-year study. Rheumatology. 1999, 38: 1138-1141. 10.1093/rheumatology/38.11.1138.CrossRefPubMed Jantti J, Aho K, Kaarela K, Kautiainen H: Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20-year study. Rheumatology. 1999, 38: 1138-1141. 10.1093/rheumatology/38.11.1138.CrossRefPubMed
7.
go back to reference Badley EM, Wang PP: The contribution of arthritis and arthritis disability to nonparticipation in the labor force: a Canadian example. J Rheumatol. 2001, 28: 1077-1082.PubMed Badley EM, Wang PP: The contribution of arthritis and arthritis disability to nonparticipation in the labor force: a Canadian example. J Rheumatol. 2001, 28: 1077-1082.PubMed
8.
go back to reference Lacaille D, Hogg RS: The effect of arthritis on working life expectancy. J Rheumatol. 2001, 28: 2315-2319.PubMed Lacaille D, Hogg RS: The effect of arthritis on working life expectancy. J Rheumatol. 2001, 28: 2315-2319.PubMed
9.
go back to reference Wolfe F, Michaud K, Choi HK, Williams R: Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol. 2005, 32: 1875-1883.PubMed Wolfe F, Michaud K, Choi HK, Williams R: Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol. 2005, 32: 1875-1883.PubMed
10.
go back to reference Allaire S, Wolfe F, Niu J, Lavalley M, Michaud K: Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum. 2005, 53: 603-608. 10.1002/art.21326.CrossRefPubMed Allaire S, Wolfe F, Niu J, Lavalley M, Michaud K: Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum. 2005, 53: 603-608. 10.1002/art.21326.CrossRefPubMed
11.
go back to reference de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BAC, Lankhorst GJ, Frings-Dresen MHW: Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004, 63: 1362-1367. 10.1136/ard.2003.020115.PubMedCentralCrossRefPubMed de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BAC, Lankhorst GJ, Frings-Dresen MHW: Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004, 63: 1362-1367. 10.1136/ard.2003.020115.PubMedCentralCrossRefPubMed
12.
go back to reference Eberhardt K, Larsson B-M, Nived K, Lindqvist E: Work disability in rheumatoid arthritis – Development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007, 34: 481-487.PubMed Eberhardt K, Larsson B-M, Nived K, Lindqvist E: Work disability in rheumatoid arthritis – Development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007, 34: 481-487.PubMed
13.
go back to reference Kessler RC, Maclean JR, Petukhova M, Sarawate CA, Short L, Li TT, Stang PE: The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples. J Occup Environ Med. 2008, 50: 88-98. 10.1097/JOM.0b013e31815bc1aa.CrossRefPubMed Kessler RC, Maclean JR, Petukhova M, Sarawate CA, Short L, Li TT, Stang PE: The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples. J Occup Environ Med. 2008, 50: 88-98. 10.1097/JOM.0b013e31815bc1aa.CrossRefPubMed
14.
go back to reference Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, Schulenburg von der JM: Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology. 2008, 47: 188-193. 10.1093/rheumatology/kem317.CrossRefPubMed Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, Schulenburg von der JM: Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology. 2008, 47: 188-193. 10.1093/rheumatology/kem317.CrossRefPubMed
15.
go back to reference Escorpizo R, Bombardier C, Boonen A, Hazes JW, Lacaille D, Strand V, Beaton D: Worker productivity outcome measures in arthritis. J Rheumatol. 2007, 34: 1372-1380.PubMed Escorpizo R, Bombardier C, Boonen A, Hazes JW, Lacaille D, Strand V, Beaton D: Worker productivity outcome measures in arthritis. J Rheumatol. 2007, 34: 1372-1380.PubMed
16.
go back to reference Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek H-P, Innes A, Strand V: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009, 68: 805-811. 10.1136/ard.2008.099291.PubMedCentralCrossRefPubMed Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek H-P, Innes A, Strand V: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009, 68: 805-811. 10.1136/ard.2008.099291.PubMedCentralCrossRefPubMed
17.
go back to reference Keystone E, Heijde van der D, Mason D, Landewé R, van Vollenhoven R, Combe B, Emery P, Strand P, Mease P, Desai C, Pavelka K: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: the RAPID 1 study. Arthritis Rheum. 2008, 58: 3319-3329. 10.1002/art.23964.CrossRefPubMed Keystone E, Heijde van der D, Mason D, Landewé R, van Vollenhoven R, Combe B, Emery P, Strand P, Mease P, Desai C, Pavelka K: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: the RAPID 1 study. Arthritis Rheum. 2008, 58: 3319-3329. 10.1002/art.23964.CrossRefPubMed
18.
go back to reference Smolen J, Landewé R, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven F, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, Heijdeet van der D: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009, 68: 797-804. 10.1136/ard.2008.101659.PubMedCentralCrossRefPubMed Smolen J, Landewé R, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven F, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, Heijdeet van der D: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009, 68: 797-804. 10.1136/ard.2008.101659.PubMedCentralCrossRefPubMed
19.
go back to reference Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F: The American College of Rheumatology Core Set of Disease Activity Measures for Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993, 36: 729-740. 10.1002/art.1780360601.CrossRefPubMed Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F: The American College of Rheumatology Core Set of Disease Activity Measures for Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993, 36: 729-740. 10.1002/art.1780360601.CrossRefPubMed
20.
go back to reference Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992, 35: 498-502. 10.1002/art.1780350502.CrossRefPubMed Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992, 35: 498-502. 10.1002/art.1780350502.CrossRefPubMed
21.
go back to reference Fries JF, Spitz P, Kraines RG, Homan HR: Measurement of patient outcomes in arthritis. Arthritis Rheum. 1980, 23: 137-145. 10.1002/art.1780230202.CrossRefPubMed Fries JF, Spitz P, Kraines RG, Homan HR: Measurement of patient outcomes in arthritis. Arthritis Rheum. 1980, 23: 137-145. 10.1002/art.1780230202.CrossRefPubMed
22.
go back to reference Bruce B, Fries JF: The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005, 23: S14-S18.PubMed Bruce B, Fries JF: The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005, 23: S14-S18.PubMed
23.
go back to reference Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA: Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993, 20: 557-560.PubMed Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA: Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993, 20: 557-560.PubMed
24.
go back to reference Redelmeier DA, Lorig K: Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med. 1993, 153: 1337-1342. 10.1001/archinte.153.11.1337.CrossRefPubMed Redelmeier DA, Lorig K: Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med. 1993, 153: 1337-1342. 10.1001/archinte.153.11.1337.CrossRefPubMed
25.
go back to reference Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed
26.
go back to reference Ware JE, Snow KK, Kosinski M: SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1. 2001, Lincoln, RI: Quality Metric Incorporated, 2 Ware JE, Snow KK, Kosinski M: SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1. 2001, Lincoln, RI: Quality Metric Incorporated, 2
27.
go back to reference Barber JA, Thompson SG: Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000, 19: 3219-3236. 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P.CrossRefPubMed Barber JA, Thompson SG: Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000, 19: 3219-3236. 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P.CrossRefPubMed
28.
go back to reference Cohen J: Statistical Power Analysis for the Behavioral Sciences. 1988, Hillsdale, NJ: Lawrence Erlbaum Associates, 2 Cohen J: Statistical Power Analysis for the Behavioral Sciences. 1988, Hillsdale, NJ: Lawrence Erlbaum Associates, 2
29.
go back to reference Kirwan JR, Ahlmen M, De Wit M, Heiberg T, Hehir M, Hewlett S, Katz PP, Minnock P, Quest EM, Richards P: Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. J Rheumatol. 2005, 32: 2246-2249.PubMed Kirwan JR, Ahlmen M, De Wit M, Heiberg T, Hehir M, Hewlett S, Katz PP, Minnock P, Quest EM, Richards P: Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. J Rheumatol. 2005, 32: 2246-2249.PubMed
30.
go back to reference Lacaille D, White MA, Backman CL, Gignac MA: Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum. 2007, 57: 1269-1279. 10.1002/art.23002.CrossRefPubMed Lacaille D, White MA, Backman CL, Gignac MA: Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum. 2007, 57: 1269-1279. 10.1002/art.23002.CrossRefPubMed
31.
go back to reference Boers M, Brooks P, Strand CV, Tugwell P: The OMERACT filter for outcome measures in rheumatology. J Rheumatol. 1998, 25: 198-199.PubMed Boers M, Brooks P, Strand CV, Tugwell P: The OMERACT filter for outcome measures in rheumatology. J Rheumatol. 1998, 25: 198-199.PubMed
32.
go back to reference Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS: The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med. 2001, 43: 218-225. 10.1097/00043764-200103000-00009.CrossRefPubMed Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS: The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med. 2001, 43: 218-225. 10.1097/00043764-200103000-00009.CrossRefPubMed
33.
go back to reference Pleis JR, Lethbridge-Çejku M: Summary health statistics for U.S. adults: National Health Interview Survey, 2006. Vital Health Stat. 2007, 1-153. Pleis JR, Lethbridge-Çejku M: Summary health statistics for U.S. adults: National Health Interview Survey, 2006. Vital Health Stat. 2007, 1-153.
34.
go back to reference Stewart WF, Lipton RB, Dowson AJ, Sawyer J: Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001, 56: S20-28.CrossRefPubMed Stewart WF, Lipton RB, Dowson AJ, Sawyer J: Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001, 56: S20-28.CrossRefPubMed
35.
go back to reference Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D: Cost of lost productive work time among US workers with depression. JAMA. 2003, 289: 3135-3144. 10.1001/jama.289.23.3135.CrossRefPubMed Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D: Cost of lost productive work time among US workers with depression. JAMA. 2003, 289: 3135-3144. 10.1001/jama.289.23.3135.CrossRefPubMed
36.
go back to reference Osterhaus JT, Gutterman DL, Plachetka JR: Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992, 2: 67-76. 10.2165/00019053-199202010-00008.CrossRefPubMed Osterhaus JT, Gutterman DL, Plachetka JR: Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992, 2: 67-76. 10.2165/00019053-199202010-00008.CrossRefPubMed
37.
go back to reference Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993, 4: 353-365. 10.2165/00019053-199304050-00006.CrossRefPubMed Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993, 4: 353-365. 10.2165/00019053-199304050-00006.CrossRefPubMed
38.
go back to reference Lerner DJ, Lee J: Measuring health related work productivity with self-reports. Health and Work Productivity: Making the Business Case for Quality Health Care. Edited by: Kessler RC, Stang PE. 2006, Chicago, IL: University of Chicago Press, 67-87. Lerner DJ, Lee J: Measuring health related work productivity with self-reports. Health and Work Productivity: Making the Business Case for Quality Health Care. Edited by: Kessler RC, Stang PE. 2006, Chicago, IL: University of Chicago Press, 67-87.
39.
go back to reference Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D: The Work Limitations Questionnaire. Med Care. 2001, 39: 72-85. 10.1097/00005650-200101000-00009.CrossRefPubMed Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D: The Work Limitations Questionnaire. Med Care. 2001, 39: 72-85. 10.1097/00005650-200101000-00009.CrossRefPubMed
40.
go back to reference Stewart WF, Ricci JA, Chee E, Morganstein D: Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003, 45: 1234-1246. 10.1097/01.jom.0000099999.27348.78.CrossRefPubMed Stewart WF, Ricci JA, Chee E, Morganstein D: Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003, 45: 1234-1246. 10.1097/01.jom.0000099999.27348.78.CrossRefPubMed
41.
go back to reference Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, Pronk N, Simon G, Stang P, Ustun TB, Wang P: The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003, 45: 156-174. 10.1097/01.jom.0000052967.43131.51.CrossRefPubMed Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, Pronk N, Simon G, Stang P, Ustun TB, Wang P: The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003, 45: 156-174. 10.1097/01.jom.0000052967.43131.51.CrossRefPubMed
Metadata
Title
Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA)
Authors
Jane T Osterhaus
Oana Purcaru
Lance Richard
Publication date
01-06-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 3/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2702

Other articles of this Issue 3/2009

Arthritis Research & Therapy 3/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.